EGFR and colorectal carcinoma: To show that the identified transcriptional changes are indeed conferring SR, we chose to therapeutically address in a proof-of-concept experiment two novel anti-EGFR secondary resistance mechanisms, which to date have not been described for CRC in this context, involving the cAMP and FGFR signaling pathways.